Only a triplet regimen comprising RT+NKG2A blockade+anti-PD−1 therapy improved the survival rate of B16F10 mice, although the improvement was related to T cells rather than NK cells.199,202 Treating irradiated B16F10 tumors with α-CD16/α-4-1BB NPs, designed to simultaneously activate two costimulatory receptors, was shown to lead to greater tumor volume reduction than treatment with a mixture of α-CD16 NPs and α-4-1BB NPs.201 The combination of RT and an ATR inhibitor (ATRi) increased NK cell activation and TIGIT expression in NK cells in HNSCC patients. Here, PDCD1 is linked to neoplasm.